Radius Health Inc (RDUS) was Downgraded by Maxim Group to ” Sell” and the brokerage firm has set the Price Target at $24. Earlier the firm had a rating of “Hold ” on the company shares. Maxim Group advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on Radius Health Inc. H.C. Wainwright Initiated Radius Health Inc on May 23, 2016 to “Buy”, Price Target of the shares are set at $55.
On the company’s financial health, Radius Health Inc reported $-1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.94.During the same quarter in the previous year, the company posted $-0.61 EPS.
Radius Health Inc opened for trading at $46.9 and hit $49.55 on the upside on Tusday, eventually ending the session at $48.98, with a gain of 4.19% or 1.97 points. The heightened volatility saw the trading volume jump to 10,05,597 shares. Company has a market cap of $2,108 M.
In a different news, on Jan 27, 2016, Lorraine A. Fitzpatrick (Chief Medical Officer) purchased 200 shares at $49.28 per share price. According to the SEC, on Nov 25, 2015, Robert Ward (President & CEO) sold 25,000 shares at $62.76 per share price. On Nov 13, 2015, Gary Hattersley (Chief Scientific Officer) sold 5,683 shares at $75.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.